Growth Pill

Entry barriers and revenue losses in the US, Europe and emerging markets have compelled pharma companies to lean on India

- NEETU CHANDRA SHARMA

PHARMA COMPANIES ARE shifting their attention to the Indian market as they see declining revenues in the US, European and emerging markets. Realising there is a significant opportunity for healthy revenues domestically, mid-sized companies like Eris Lifesciences and the recently-listed Mankind Pharma are also keeping an eye on the Indian market, joining the likes of market heavyweights Sun Pharma, Dr. Reddy’s and Cipla, among others.